NVS vs. RVTY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NVS and RVTY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
NVS trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RVTY is a standard domestic listing.
| Symbol | NVS | RVTY |
|---|---|---|
| Company Name | Novartis AG | Revvity, Inc. |
| Country | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Market Capitalization | 254.99 billion USD | 10.65 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | November 7, 1996 | February 21, 1973 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of NVS and RVTY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NVS | RVTY |
|---|---|---|
| 5-Day Price Return | 2.34% | 3.74% |
| 13-Week Price Return | 2.27% | -9.38% |
| 26-Week Price Return | 2.04% | -18.36% |
| 52-Week Price Return | 9.24% | -30.47% |
| Month-to-Date Return | -1.03% | -2.73% |
| Year-to-Date Return | 12.87% | -21.47% |
| 10-Day Avg. Volume | 2.80M | 1.32M |
| 3-Month Avg. Volume | 2.81M | 1.25M |
| 3-Month Volatility | 18.12% | 40.14% |
| Beta | -0.01 | 1.01 |
Profitability
Return on Equity (TTM)
NVS
32.56%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
In the upper quartile for the Pharmaceuticals industry, NVS’s Return on Equity of 32.56% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
RVTY
3.71%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
RVTY’s Return on Equity of 3.71% is in the lower quartile for the Life Sciences Tools & Services industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
NVS
24.90%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 24.90% places NVS in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
RVTY
10.19%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
RVTY’s Net Profit Margin of 10.19% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
NVS
30.03%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
An Operating Profit Margin of 30.03% places NVS in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RVTY
13.57%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
RVTY’s Operating Profit Margin of 13.57% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | NVS | RVTY |
|---|---|---|
| Return on Equity (TTM) | 32.56% | 3.71% |
| Return on Assets (TTM) | 13.32% | 2.29% |
| Net Profit Margin (TTM) | 24.90% | 10.19% |
| Operating Profit Margin (TTM) | 30.03% | 13.57% |
| Gross Profit Margin (TTM) | 76.12% | 55.93% |
Financial Strength
Current Ratio (MRQ)
NVS
0.82
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
NVS’s Current Ratio of 0.82 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RVTY
3.33
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
RVTY’s Current Ratio of 3.33 is in the upper quartile for the Life Sciences Tools & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
NVS
0.77
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
NVS’s Debt-to-Equity Ratio of 0.77 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RVTY
0.43
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
RVTY’s Debt-to-Equity Ratio of 0.43 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
NVS
22.55
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
NVS’s Interest Coverage Ratio of 22.55 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
RVTY
15.30
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
RVTY’s Interest Coverage Ratio of 15.30 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | NVS | RVTY |
|---|---|---|
| Current Ratio (MRQ) | 0.82 | 3.33 |
| Quick Ratio (MRQ) | 0.62 | 2.75 |
| Debt-to-Equity Ratio (MRQ) | 0.77 | 0.43 |
| Interest Coverage Ratio (TTM) | 22.55 | 15.30 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NVS
3.27%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
NVS’s Dividend Yield of 3.27% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
RVTY
0.32%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
RVTY’s Dividend Yield of 0.32% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
NVS
102.24%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
NVS’s Dividend Payout Ratio of 102.24% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
RVTY
11.88%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
RVTY’s Dividend Payout Ratio of 11.88% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | NVS | RVTY |
|---|---|---|
| Dividend Yield (TTM) | 3.27% | 0.32% |
| Dividend Payout Ratio (TTM) | 102.24% | 11.88% |
Valuation
Price-to-Earnings Ratio (TTM)
NVS
17.49
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
NVS’s P/E Ratio of 17.49 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RVTY
36.78
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
RVTY’s P/E Ratio of 36.78 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
NVS
4.35
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
NVS’s P/S Ratio of 4.35 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RVTY
3.75
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
RVTY’s P/S Ratio of 3.75 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
NVS
6.06
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
NVS’s P/B Ratio of 6.06 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
RVTY
1.51
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
RVTY’s P/B Ratio of 1.51 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | NVS | RVTY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 17.49 | 36.78 |
| Price-to-Sales Ratio (TTM) | 4.35 | 3.75 |
| Price-to-Book Ratio (MRQ) | 6.06 | 1.51 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.21 | 20.85 |